Description: Thinking about whether Viatris could be a hidden gem or a value trap? Let’s dig into what the numbers, news, and recent price trends suggest about its real worth. Shares of Viatris have slipped 1.4% over the past week, even though they rose 2.0% across the last month. This hints at changing sentiment and perhaps brewing growth potential or shifting risk perceptions. News around Viatris this month highlighted their ongoing efforts to streamline operations and optimize their product portfolio...

Description: Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Description: Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t

Description: NORTHAMPTON, MA / ACCESS Newswire / November 18, 2025 / Viatris takes a multi-pronged approach to actively engage in addressing AMR, both by providing access through our portfolio of more than 90 antimicrobials and in partnership with others, including ...

Description: Viatris (VTRS) grabbed the spotlight after posting third quarter revenues that came in ahead of expectations and raising its guidance for both full-year revenue and adjusted EBITDA. See our latest analysis for Viatris. Momentum has picked up for Viatris in recent weeks, especially after management doubled down on growth ambitions and raised guidance. These moves sparked a 9.9% jump in the share price over the past month alone. Despite year-to-date and one-year total shareholder returns still...

Description: Viatris has seen its Fair Value Estimate nudge higher from $12.00 to $12.13 as analysts revise their assumptions for the company's future growth and market opportunities. This modest upward adjustment reflects improved revenue expectations and reduced business risk, along with growing optimism about Viatris's ability to execute on its initiatives. Stay tuned to discover how ongoing shifts in analyst sentiment may impact your understanding of Viatris’s evolving narrative in the months...

Description: Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025. The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 million responses representing more than 25 million employees worldwide. To be considered for the list, companies must have 5,000 or more global employees, be identified as outstanding global employers with recognition on at least

Description: We recently published 10 Stocks on a Hot Streak. Viatris Inc. (NASDAQ:VTRS) is one of the best-performing stocks on Tuesday. Viatris rallied for a third day on Tuesday, jumping 10.13 percent to close at $11.20 apiece after reaffirming its growth targets at the recently concluded UBS Healthcare Conference. According to the company, it targets to […]

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.

Description: Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Art

Description: Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025.

Description: Viatris Inc. recently reported strong third quarter 2025 results, raising its full-year guidance to US$13.9–14.3 billion in revenue and increasing anticipated adjusted earnings per share, supported by contributions from new products and the acquisition of Aculys Pharma. Management emphasized its ongoing pursuit of growth-focused mergers and acquisitions, while also reaffirming a commitment to shareholder returns through dividends and share repurchases exceeding US$920 million...

Description: Scott Andrew Smith: We delivered another strong quarter by focusing on our 2025 strategic priorities. Driving strong commercial execution, advancing our pipeline, returning capital to shareholders through dividends and share repurchases, pursuing end-market business development opportunities, and advancing our enterprise-wide strategic review to identify opportunities to deliver meaningful net cost savings.

Description: Key market opportunities for needle-free devices lie in technological advancements, regional expansion across Asia-Pacific and MEA, and growing applications in vaccines, pain management, and insulin delivery. Strategic alliances and innovations from major players like GSK and Novartis can further drive growth. Global Needle-Free Devices Market Global Needle-Free Devices Market Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Needle-Free Devices: Technologies and Global Markets" has been added to R

Description: Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.

Description: The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.67 per share was 8.5% above analysts’ consensus estimates.

Description: CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $128.2 million in its third quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of 11 cents.

Description: Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance.

Description: Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Description: Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know.

Description: NORTHAMPTON, MA / ACCESS Newswire / November 4, 2025 / Public policies are central factors in determining healthcare interventions and access to medicines and treatment. Viatris leverages our global experiences, scientific expertise and operations ...

Description: Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.

Description: Viatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 15, 2025, to shareholders of record as of the close of business on November 24, 2025.

Description: Viatris (VTRS) just announced a strategic partnership with Locus Biosciences to develop new bacteriophage therapies for drug-resistant eye infections. The collaboration brings together cutting-edge AI and synthetic biology, providing new alternatives to traditional antibiotics. See our latest analysis for Viatris. Viatris’s recently announced partnership to tackle drug-resistant infections is catching attention at a time when its stock is trying to regain momentum. After some challenging...

Description: Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Description: NORTHAMPTON, MA / ACCESS Newswire / October 28, 2025 / Antimicrobial resistance (AMR) is a significant global health challenge impacting millions of people around the world and with the potential to lead to even greater disruptions to care if not ...

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: RESEARCH TRIANGLE PARK, N.C., October 28, 2025--Locus Biosciences announced a research collaboration with Viatris to develop engineered bacteriophage therapies for ophthalmic infections.

Description: Viatris will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Description: Viatris Inc. (NASDAQ:VTRS) is one of the best large cap stocks to buy under $20. On October 15, Truist’s Les Sulewski initiated coverage of Viatris with a Buy rating and $15 price target. Truist acknowledges that concerns regarding legacy Viatris are still prevalent across the franchise. However, the firm maintains that there is an affirmative […]

Description: Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

Description: Viatris’s 35.8% return over the past six months has outpaced the S&P 500 by 8.4%, and its stock price has climbed to $10.44 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Description: Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: NORTHAMPTON, MA / ACCESS Newswire / October 21, 2025 / Viatris has a long history in the fight against infectious disease, which accounts for eight of the top 10 causes of death in low-income countries.1 We are working with global and local partners ...

Description: ​Viatris Inc. (NASDAQ:VTRS) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 15, Viatris Inc. (NASDAQ:VTRS) announced completing the acquisition of Aculys Pharma, Inc., which is a clinical-stage biopharmaceutical company. ​Aculys Pharma, Inc. is commercializing innovative treatments for neurological conditions. Management noted that, as a result of this acquisition, […]

Description: Viatris stock has seen its Fair Value Estimate rise slightly from $11.43 to $11.88 per share, reflecting cautious optimism among analysts. This modest increase follows incremental improvements in the company's revenue growth forecast and a positive response to new product rollouts. Stay tuned to discover how you can track ongoing updates to Viatris's evolving market narrative. What Wall Street Has Been Saying 🐂 Bullish Takeaways Needham upgraded Amphastar after the FDA approval of AMP-002...